Viropro: precisions on the Alpha acquisition.

On 22 Feb 2011, Viropro announced that it had acquired Alpha Biologics Sdn (Alpha) of Penang Malaysia. In that press release, Viropro stated that the value of the plant would be reappraised to better reflect its true value; some investors were led to believe that Viropro would have to increase the number of shares issued as payment. Viropro therefore clarifies and confirms that its acquisition cost for the plant will remain at 525 M shares whether or not value of the plan is reappraised. Viropro also reemphasizes that it is currently processing all data pertaining to financial statements so as to disclose them as soon as possible and will from there undertake all necessary measures to …